抗Human IL6ST 抗体:
抗Mouse (Murine) IL6ST 抗体:
抗Rat (Rattus) IL6ST 抗体:
Human Monoclonal IL6ST Primary Antibody for FACS, IP - ABIN1383683
Wijdenes, Heinrich, Müller-Newen, Roche, Gu, Clément, Klein: Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. in European journal of immunology 1996
Show all 26 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS, IP - ABIN1383685
Fourcin, Chevalier, Guillet, Robledo, Froger, Pouplard-Barthelaix, Gascan: gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses. in The Journal of biological chemistry 1996
Show all 24 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383678
Gu, Wijdenes, Zhang, Hallet, Clement, Klein: Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. in Journal of immunological methods 1996
Show all 19 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383682
Chevalier, Fourcin, Robledo, Wijdenes, Pouplard-Barthelaix, Gascan: Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. in The Journal of biological chemistry 1996
Show all 15 Pubmed References
Mouse (Murine) Monoclonal IL6ST Primary Antibody for CyTOF, FACS - ABIN4899764
Bailey, Huang, Kam, Farzan: Ifitm3 limits the severity of acute influenza in mice. in PLoS pathogens 2012
Show all 7 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383681
Auguste, Guillet, Fourcin, Olivier, Veziers, Pouplard-Barthelaix, Gascan: Signaling of type II oncostatin M receptor. in The Journal of biological chemistry 1997
Show all 5 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383684
Müller-Newen, Köhne, Keul, Hemmann, Müller-Esterl, Wijdenes, Brakenhoff, Hart, Heinrich: Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. in European journal of biochemistry / FEBS 1996
Show all 4 Pubmed References
Mouse (Murine) Monoclonal IL6ST Primary Antibody for FACS - ABIN4896627
Pratama, Srivastava, Williams, Papa, Lee, Dinh, Hutloff, Jordan, Zhao, Casellas, Athanasopoulos, Vinuesa: MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. in Nature communications 2015
Show all 4 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383679
Menetrier-Caux, Thomachot, Alberti, Montmain, Blay: IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. in Cancer research 2001
Show all 3 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN4897911
Larsen, Hansen, Møller, Madsen, Scheller, Nielsen, Petersen: Sortilin facilitates signaling of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor receptor beta heterodimer. in Molecular and cellular biology 2010
Show all 3 Pubmed References
Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.
Low plasma IL6ST level is associated with poor response to sunitinib in metastatic clear cell renal cell carcinoma.
Multiple MSI2-regulated mRNAs have been identified, and evidence has been provided that MSI2 controls IL6ST activity that control oncogenic signaling networks.
Blocking the interaction between IL-6 and GP130 may inhibit the IL-6/GP130/STAT3 signaling pathway.
findings indicate that even though high concentrations of sIL-6R and sgp130 are present in human serum, the relative ratio of free IL-6 to IL-6.sIL-6R allows for simultaneous classic and trans-signaling
Results show that gastric tumourigenesis as a consequence of hyperactive gp130/STAT3 signaling, is intrinsically linked with the development of submucosal tertiary lymphoid structures (TLSs) in gastric antrum tissue.
Low soluble glycoprotein 130 (sgp130) level may serve as an additional indicator of coronary atherosclerosis severity.
we show by molecular replacement that Arg-112 does not participate in binding of IL-11 to its receptors IL-11R and glycoprotein 130 (gp130). Recombinant IL-11 R112H expressed in E. coli displays a correct four-helix-bundle folding topology, and binds with similar affinity to IL-11R and the IL-11/IL-11R/gp130 complex.
SNP rs10940495 in the gp130 locus was associated with functional outcome at 6 months following spontaneous intracerebral hemorrhage.
Low levels of serum sgp130 were positively associated with sex hormones in male patients with coronary artery disease, suggesting an important role of sgp130 in the presence of low and imbalanced sex hormones levels.
Decreased serum LIF levels may be associated with vasculopathy in systemic sclerosis (SSc) and that Fli1 deficiency may contribute to the inhibition of LIF-dependent biological effects on SSc endothelial cells by suppressing the expression of LIF, LIF receptor, and gp130.
gp130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer.
GP130 signaling is required for tumor cell survival in diverse forms of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Data show that tumor suppressor adenomatous polyposis coli (APC) loss results in up-regulation of IL-6 signal transducer (IL-6ST/gp130), thereby activating YAP (YY1-associated) protein (YAP) which are simultaneously up-regulated in the majority of colorectal cancer (CRC).
study focused on IL-6 and activation of its receptors gp80 and gp130 in human gingival fibroblasts in order to assess the effects of the commercial acid resins Jet Kit, Unifast, and Duralay on control of inflammation
an impaired oxidative stress response in hepatocytes with gp130 gain-of-function mutations, as detected in dysplastic intrahepatic nodules and hepatocellular adenomas, is one of the central oncogenic mechanisms in chronic liver inflammation.
The sgp130, IL-6, and sIL-6R concentrations were statistically significantly elevated in patients with diabetic retinopathy (DR), suggesting a probable contributing role of the IL-6 trans-signaling pathway to the pathophysiology of DR.
age 3 plasma levels of sGP130 were found related to childhood asthma
This functional mouse model of PMM2-CDG, in vitro assays and identification of the novel gp130 biomarker all shed light on the human disease, and moreover, provide the essential tools to test potential therapeutics for this untreatable disease.
we developed a CRISPR-Cas9-based tool for specific DNA methylation consisting of deactivated Cas9 (dCas9) nuclease and catalytic domain of the DNA methyltransferase DNMT3A targeted by co-expression of a guide RNA to any 20 bp DNA sequence followed by the NGG trinucleotide.we demonstrated that directed DNA methylation of a wider promoter region of the target loci IL6ST and BACH2 decreased their expression
results demonstrate that gp130-associated TRAF2 and TRAF5 inhibit the interaction between two JAK proteins in the IL-6R complex that is essential for initiating the JAK-STAT signaling pathway
Different pathology in macrophage/neutrophil- and CD4 T cell-specific gp130-deficient mice suggests that gp130 cytokines modulate TH17 inflammation differentially by targeting distinct cell types.
EBI3 can mediate IL-6 trans-signaling in a process that involves gp130
data suggest that the different sgp130 forms are released from cells into their immediate surroundings and appear to form cell-associated gradients to modulate their own susceptibility for IL-6 trans-signaling.
Blocking IL-6 trans-signaling in the CNS abrogates the ability of IL-6 to suppress feeding. Furthermore, gp130 expression is enhanced in the paraventricular nucleus of the hypothalamus (PVH) of obese mice, and deletion of gp130 in the PVH attenuates the beneficial central IL-6 effects on metabolism
C2C12 myotubes possesses a mechanism for regulating IL-6R and gp130 expression following lipoic acid treatment or heat shock.
Results suggest that the protective role of gp130-dependent STAT3 activation in experimental colitis involves the expansion and activation of mucosal myeloid-derived suppressor cells.
IL-6/gp130 signalling in the osteoclast is not essential for normal bone resorption in vivo, but maintains both trabecular and periosteal bone formation in male mice by promoting osteoblast activity through the stimulation of osteoclast-derived coupling factors and osteotransmitters
gp130-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin resistance.
differences exist in the expression of receptors utilized by the IL-6/gp130 family of cytokines in astrocytes and microglia, and (2) the findings provide a molecular basis for the differential response to oncostatin M by astrocytes versus microglia
Deregulation of gp130/STAT3 signalling augments the acute phase reponse and macrophage infiltration during atherosclerosis without impacting on the development of aortic plaques.
Significant differential expression (both increases and decreases) of multiple IL-6/gp130 cytokines, such as LIF, oncostatin-M, and ciliary neurotrophic factor, occurred after Muller cell ablation
GP130 signaling collaborated with MYC to induce MM and was responsible and sufficient for directing the plasma cell phenotype.
gp130, a co-receptor for IL-6 cytokines, triggers activation of YAP and Notch, transcriptional regulators that control tissue growth and regeneration, independently of the gp130 effector STAT3
osteocytic gp130 signaling is required for normal trabecular bone mass and proper cortical bone composition.
PGF2alpha inhibits adipocyte differentiation by means of an IL-11 mediated autocrine negative feedback loop, that acts via gp130 to block adipogenesis through the essential actions of the STAT1 transcription factor.
Osteocytic gp130 is required to maintain PTH1R expression in the osteoblast lineage, and for the stimulation of osteoblast differentiation that occurs in response to PTH.
study concludes that in a setting of islet inflammation and pathophysiology modeling type 2 diabetes, activation of alpha-cell gp130 receptor signaling has deleterious effects on alpha-cell function, promoting hyperglycemia.
The expression of IL-6, IL-6R and gp130 transcripts were detected very early, increased during the first week of life and were predominantly expressed in the head, epidermis and neuromasts of the anterior and posterior lateral line system.
IL-6sR and gp130, but not IL-6R alpha, play important roles in regulation of granulosa cell survival
The protein encoded by this gene is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM). This protein functions as a part of the cytokine receptor complex. The activation of this protein is dependent upon the binding of cytokines to their receptors. vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, can bypass the interleukin 6 receptor (IL6R) and directly activate this protein. Knockout studies in mice suggest that this gene plays a critical role in regulating myocyte apoptosis. Alternatively spliced transcript variants encoding distinct isoforms have been described. A related pseudogene has been identified on chromosome 17.
, IL-6 receptor subunit beta
, IL-6R subunit beta
, gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form
, interleukin receptor beta chain
, interleukin-6 receptor subunit beta
, membrane glycoprotein 130
, membrane glycoprotein gp130
, oncostatin-M receptor subunit alpha
, interleukin-6 signal transducer
, interleukin 6 signal transducer
, glycoprotein 130
, LOW QUALITY PROTEIN: interleukin-6 receptor subunit beta
, interleukin 6 signal transducer (gp130, oncostatin M receptor)
, interleukin 6 signal transducer receptor